Nexus Investments’ Scale-Up Fund

Hardman & Co

Why Invest

Positives

  • Strategy: To fund fast-growth companies in data, digital, education and healthcare, which have existing products, and support them in scaling up.

Issues

  • Track record: No exits to date from the current set-up, but the unrealised figures show some promise. Nexus Group has had exits from earlier investments.

The Investment Manager

Positives

  • Team: The team has a broad experience in corporate finance, tax and accounting, as well as investment. The Nexus Group also manages a £2.3bn healthcare REIT.

Issues

  • Small team: The team is small, and is dependent on a couple of key people, although it is part of the much larger Nexus Group.

Nuts & Bolts

  • Duration: The fund is expected to have a lifespan of up to eight years, with closings as required.
  • Diversification: The manager expects to provide each investor with 8 to 10 EIS investments, although that range may be exceeded.
  • Valuation: Reviewed twice a year, with updates on progress being sent more frequently.

Specific Issues

  • Fees: A mixture of direct fees and those charged to the investee companies.
  • Performance fee: Charged on a portfolio basis at 20% for returns over £1.

Risks

  • Target returns: The target return is 2.5x capital, which suggests a high-risk investment strategy.
  • Companies: Supplying risk capital to early-stage technology companies at the start of commercialisation. There will be a spread of company returns, as the successful investments will do very well, but those that fail may do so completely.

DOWNLOAD THE FULL REPORT

Share on:
Find more news, interviews, share price & company profile here for:

    JPMorgan European Discovery Trust reports strong performance uplift in latest factsheet

    JPMorgan European Discovery Trust reported a 5.37% share price rise in July 2025, outpacing NAV and its benchmark. Year-to-date, the share price is up 34.17%, supported by strong small-cap performance and effective stock selection.

    Golden Matrix reports record August revenue of $17.8m, up 18% year-on-year

    Golden Matrix posted record August revenues of $17.8m, up 18% from last year, with July revenues also rising 24% to $15.7m. Strong performance came from Meridianbet’s sports betting and RKings’ tournaments, positioning the group for record Q3 results.

    HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

    HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653.

    Surface Transforms appoints Paul Marr as Non-Executive Director

    Surface Transforms has appointed Paul Marr to its Board as Non-Executive Director. Marr brings over 40 years of global automotive manufacturing and operational leadership experience, including senior roles at General Motors and other international groups.

    Avation signs 12-year lease for ATR 72-600 with Cambodian airline

    Avation has agreed a twelve-year lease with a Cambodian carrier for a new ATR 72-600, the second of ten aircraft ordered in 2024. Delivery is scheduled for February 2026.

    Tern Plc delivers stronger interim results with reduced loss and portfolio growth

    Tern Plc reported improved interim results for the six months to 30 June 2025, with a 64% reduction in loss, disciplined cost control, and a new strategic investment in Sure Ventures plc. The company also strengthened portfolio support through successful fundraises.

      Search

      Search